Arbutus Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	153.05	-33.5	-69.92	-72.85	-69.46	-76.25
Depreciation & Amortization	0.04	0.36	1.38	1.4	1.43	1.75
Stock-Based Compensation	5.51	6.95	8.99	9.3	7.18	6.42
Other Adjustments	-4.4	-3.43	-2.47	-5.56	-3.75	-0.39
Change in Receivables	-178.3	1.38	-0.63	-0.42	-0.45	0.41
Changes in Accounts Payable	-1.66	-2.11	-2.71	-5.76	5.22	1.91
Changes in Unearned Revenue	-	-10.43	-1.36	-10.66	22.46	-
Changes in Other Operating Activities	1.81	1.14	1.87	-1.39	2.03	-1.4
Operating Cash Flow	-24.63	-39.64	-64.85	-85.94	-35.36	-67.53
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-	-	-0.18	-1.01	-0.51	-0.81
Sale of Property, Plant & Equipment	0.36	0.36	-	0.02	-	-
Purchases of Investments	-114.31	-140.06	-141.51	-80.51	-130.43	-82.22
Proceeds from Sale of Investments	103.11	155.28	164.64	132.27	56	70.35
Investing Cash Flow	-10.84	15.58	22.95	50.77	-74.94	-12.68
Issuance of Common Stock	17.25	5.72	52	30.65	31.81	137.24
Net Common Stock Issued (Repurchased)	17.25	5.72	52	30.65	31.81	137.24
Financing Cash Flow	17.25	5.72	52	30.65	31.81	137.24
Foreign Exchange Rate Adjustments	-0.03	0.01	-0.05	0.03	-0.02	0.01
Net Cash Flow	-18.24	-18.32	10.05	-4.49	-78.51	57.03
Free Cash Flow	-24.63	-39.64	-65.03	-86.94	-35.87	-68.34
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-13.55%	-281.45%	-1053.83%	-479.27%	-91.92%	-621.96%
Free Cash Flow Per Share	-0.13	-0.21	-0.35	-0.52	-0.24	-0.64
Levered Free Cash Flow	153.25	-44.54	-70.92	-90.26	-38.85	-86.93
Unlevered Free Cash Flow	149.19	-49.2	-77.32	-95.52	-30.37	-72.07

SEC Filings: 10-K · 10-Q